KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Exact Sciences (EXAS) over the last 17 years, with Q3 2025 value amounting to $789.0 million.

  • Exact Sciences' Cash & Equivalents rose 3400.08% to $789.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.0 million, marking a year-over-year increase of 3400.08%. This contributed to the annual value of $600.9 million for FY2024, which is 74.15% down from last year.
  • Latest data reveals that Exact Sciences reported Cash & Equivalents of $789.0 million as of Q3 2025, which was up 3400.08% from $657.1 million recorded in Q2 2025.
  • In the past 5 years, Exact Sciences' Cash & Equivalents ranged from a high of $1.1 billion in Q1 2021 and a low of $189.8 million during Q1 2022
  • In the last 5 years, Exact Sciences' Cash & Equivalents had a median value of $421.4 million in 2023 and averaged $475.0 million.
  • As far as peak fluctuations go, Exact Sciences' Cash & Equivalents tumbled by 8280.73% in 2022, and later skyrocketed by 18317.88% in 2023.
  • Over the past 5 years, Exact Sciences' Cash & Equivalents (Quarter) stood at $315.5 million in 2021, then fell by 23.13% to $242.5 million in 2022, then surged by 149.65% to $605.4 million in 2023, then dropped by 0.74% to $600.9 million in 2024, then soared by 31.31% to $789.0 million in 2025.
  • Its Cash & Equivalents was $789.0 million in Q3 2025, compared to $657.1 million in Q2 2025 and $347.1 million in Q1 2025.